1. Fulfilling the mandate of the US Food and Drug Administration’s accelerated approval pathway: the need for reforms.;Gyawali;JAMA Intern Med,2021
2. “Dangling” accelerated approvals in oncology.;Beaver;N Engl J Med,2021
3. How much favorable selection is left in Medicare Advantage?;Newhouse;Am J Health Econ,2015
4. US Food and Drug Administration. Expedited programs for serious conditions—drugs and biologics. Published June 25, 2020. Accessed May 26, 2021. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expedited-programs-serious-conditions-drugs-and-biologics
5. Pazdur? R. FDA in Brief: FDA Oncologic Drugs Advisory Committee to review status of six indications granted accelerated approval. Published March 15, 2021. Accessed March 23, 2021. https://www.fda.gov/news-events/fda-brief/fda-brief-fda-oncologic-drugs-advisory-committee-review-status-six-indications-granted-accelerated